In advanced human liver cancer (hepatocellular carcinoma, HCC), there is commonly ectopic TGFβ production by the malignant hepatocytes in addition to that released by the non-parenchymal cells ([5,6]), giving rise to the idea that HCC cells have acquired a resistance to TGFβ-mediated growth inhibition. This evidence concerns the gene TGFB1 and liver cancer.